Dizlin Pharmaceuticals AB is a privately held Swedish research-based pharmaceutical development company with focus on diseases of the central nervous system in general and on developing improved treatment for advanced stages of Parkinson’s disease in particular. The company conducts research in collaboration with researchers at the University of Gothenburg and Linköping University in Sweden.
The company has developed a new patented method for treatment of advanced stages of Parkinson's disease. Dizlin Pharmaceuticals has two products in late phase development stage. The first - Infudopa IntraV™ – is administered intravenously to minimize risks associated with surgery on patients with Parkinson's disease. The second – Infudopa SubC™ – is administered as a continuous subcutaneous infusion by means of a portable pump (similar to insulin infusion for diabetes).
Company Details
- Employees
- 6
- Founded
- -
- Address
- Kungsgatan 64, Stockholm,stockholm County 11122,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.dizlin.se
- HQ
- Stockholm, Stockholm County
Dizlin Pharmaceuticals Ab Questions
Dizlin Pharmaceuticals Ab's website is http://www.dizlin.se
Dizlin Pharmaceuticals Ab's LinkedIn profile is https://se.linkedin.com/company/dizlin-pharmaceuticals-ab
Dizlin Pharmaceuticals Ab has
6 employees.
View email and phone details for 6
employees at Dizlin Pharmaceuticals Ab.
Dizlin Pharmaceuticals Ab's industry is
Pharmaceutical Manufacturing
Dizlin Pharmaceuticals Ab's top competitors are
Azurity Pharmaceuticals,
Sobi - Swedish Orphan Biovitrum Ab (Publ),
Neuraxpharm,
Jiangsu Zhengkang Medical Apparatus Co.,ltd,
Esteve,
Acino,
Clinigen,
Cellenion,
Kern Pharma,
Pharmacosmos.
Dizlin Pharmaceuticals Ab's categories are Pharmaceutical Manufacturing
Dizlin Pharmaceuticals Ab's founding year is 2008
